drugset / Trial / NCT06541405
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Phase 0
Unknown
9 enrolled
Base Therapeutics (Shanghai) Co., Ltd.
Shanghai Children's Medical Center · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of NK520 in the treatment of pediatric relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2025-06-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NK520 | Unknown | 5e+07 cells/kg | Intravenous |
| Subject | NK520 | Unknown | 1.5e+08 cells/kg | Intravenous |
| Subject | NK520 | Unknown | 3e+08 cells/kg | Intravenous |